Loading people...
Chris Chai is a Venture Partner at SR One based in the San Francisco Bay Area, where he guides life sciences portfolio companies through financing strategies, public offerings, and acquisitions. Prior to joining the venture capital firm, he served as Chief Financial Officer at Principia Biopharma, facilitating the company's $3.68 billion acquisition by Sanofi in 2020. His previous executive experience includes serving as CFO at MAP Pharmaceuticals, which was acquired by Allergan, and Vice President of Treasury and Investor Relations at CV Therapeutics, purchased by Gilead. Over two decades in biotech management, he has raised $2.3 billion across more than 20 financings, led two billion-dollar sales, and scaled operations to over 700 employees. Chai, who holds a Bachelor of Science from Cornell University and began his career at JP Morgan, also serves on the Surrozen board.
Chris Chai is a distinguished Venture Partner at SR One, a leading independent venture capital firm renowned for its deep commitment to the life sciences sector. In his pivotal role, Chris is instrumental in identifying, evaluating, and supporting innovative early-stage companies that are poised to revolutionize healthcare and biotechnology. His work directly contributes to SR One's mission of investing in groundbreaking science and technology that addresses significant unmet medical needs.
At SR One, Chris Chai focuses on a broad spectrum of life science investments, with a particular emphasis on novel therapeutics, platform technologies, and disruptive healthcare solutions. He actively seeks out companies developing cutting-edge approaches in areas such as oncology, immunology, neuroscience, and rare diseases. His expertise is crucial in assessing the scientific merit, market potential, and strategic viability of prospective investments, ensuring that SR One's portfolio comprises companies with the highest potential for impact and growth. Chris is deeply involved in the entire investment lifecycle, from initial deal sourcing and rigorous due diligence to providing strategic guidance and operational support to portfolio companies.
Chris Chai brings a wealth of experience and a profound understanding of the life sciences industry to his position. His career background encompasses a blend of scientific acumen, business development expertise, and strategic leadership within the biotechnology and pharmaceutical landscapes. This diverse experience equips him with a unique perspective, enabling him to effectively bridge the gap between scientific innovation and commercial success. He is adept at recognizing promising scientific breakthroughs and translating them into viable investment opportunities, fostering the development of therapies that can significantly improve patient outcomes.
While specific individual investments are often a collaborative effort within SR One, Chris Chai plays a vital role in shaping the firm's overall investment strategy and contributing to the success of its diverse portfolio. He works closely with founders and management teams, offering mentorship, leveraging his extensive network, and helping to navigate the complex challenges inherent in bringing novel medical innovations to market. His dedication to fostering innovation and his strategic insights are invaluable assets to SR One and the companies it supports. Through his contributions, Chris Chai continues to reinforce SR One's position as a key investor in the future of life sciences and healthcare.
Chris Chai is a Venture Partner at SR One, a prominent venture capital firm focused on life sciences. He specializes in identifying and supporting innovative early-stage companies in biotechnology and healthcare.
Chris Chai invests in a wide range of life science companies, with a focus on novel therapeutics, platform technologies, and disruptive healthcare solutions. This includes areas like oncology, immunology, neuroscience, and rare diseases.
Chris Chai works as a Venture Partner at SR One, an independent venture capital firm dedicated to investing in groundbreaking life sciences companies.
